US 12,221,625 B2
Method for producing retinal pigment epithelial cells
Satoshi Ando, Osaka (JP); and Takao Kuroda, Osaka (JP)
Assigned to SUMITOMO PHARMA CO., LTD., Osaka (JP); and HEALIOS K.K., Tokyo (JP)
Filed by SUMITOMO PHARMA CO., LTD., Osaka (JP); and HEALIOS K.K., Tokyo (JP)
Filed on Apr. 4, 2023, as Appl. No. 18/295,428.
Application 18/295,428 is a continuation of application No. 15/757,202, granted, now 11,649,432, previously published as PCT/JP2016/076524, filed on Sep. 8, 2016.
Claims priority of application No. 2015-176896 (JP), filed on Sep. 8, 2015.
Prior Publication US 2023/0287342 A1, Sep. 14, 2023
Int. Cl. A61K 35/50 (2015.01); A61K 35/30 (2015.01); A61K 35/545 (2015.01); A61L 27/00 (2006.01); C12N 5/079 (2010.01); C12Q 1/02 (2006.01); G01N 33/50 (2006.01)
CPC C12N 5/0621 (2013.01) [A61K 35/30 (2013.01); A61K 35/545 (2013.01); A61L 27/00 (2013.01); C12Q 1/02 (2013.01); G01N 33/5014 (2013.01); G01N 33/5044 (2013.01); C12N 2500/90 (2013.01); C12N 2501/115 (2013.01); C12N 2501/999 (2013.01); C12N 2506/03 (2013.01)] 24 Claims
OG exemplary drawing
 
1. A production method of a human retinal pigment epithelial cell comprising the following steps:
(1) a maintenance and/or expanding step of maintaining and/or expanding human pluripotent stem cells comprising culturing the human pluripotent stem cells in the absence of a feeder cell in a medium comprising a factor for maintaining an undifferentiated state,
(2) a first step for culturing the maintained and/or expanded human pluripotent stem cells in a medium comprising a MEK inhibitor in the absence of feeder cells for a period of not less than 2 days and not more than 30 days, wherein the culture condition in the first step is a condition sufficient for inducing gene expression of at least one eye field transcription factor, and
(3) a second step for culturing the cells obtained in the first step in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor to form a retinal pigment epithelial cell.